Mersana Therapeutics (MRSN) is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options.
There are a few reasons to get bullish on Mersana Therapeutics.
For one, according to Pfizer’s CEO Albert Bourla, ADCs have become one of the hottest opportunities in oncology, which would explain why it recently acquired Seagen for $34 billion. Even better, Pfizer wants to acquire even more ADC companies.
Two, Citi analysts recently upgraded MRSN to a Buy with a price target of $5. Given the accelerating M&A activity in the broader ADC space, the firm believes the market will be receptive to revisiting Mersana, notes TheFly.com.
Three, the company is advancing its Phase 1 clinical trial of XMT-1660, the company’s lead Dolasynthen ADC candidate targeting B7-H4. According to Cell Immunology, “B7-H4 negatively regulates T cell immune response and promotes immune escape by inhibiting the proliferation, cytokine secretion, and cell cycle of T cells.”